Literature DB >> 7937785

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

C W Yang1, H Vlassara, E P Peten, C J He, G E Striker, L J Striker.   

Abstract

Several lines of evidence suggest that the excessive accumulation of extracellular matrix in the glomeruli of diabetic kidneys may be due to reactive intermediates forming between glucose and matrix proteins called advanced glycation end products (AGEs). Normal mice received AGE-modified mouse serum albumin i.p. for 4 weeks, and glomerular extracellular matrix, growth factor mRNA levels, and morphology were examined. We found that AGE induced an increase in glomerular extracellular matrix alpha 1(IV) collagen, laminin B1, and transforming growth factor beta 1 mRNA levels, as measured by competitive PCR, as well as glomerular hypertrophy. The AGE response was specific because the coadministration of an AGE inhibitor, aminoguanidine, reduced all these changes. We conclude that AGEs affected expression of genes implicated in diabetic kidney disease and may play a major role in nephropathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937785      PMCID: PMC44827          DOI: 10.1073/pnas.91.20.9436

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

2.  Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA.

Authors:  M A Carome; L J Striker; E P Peten; J Moore; C W Yang; W G Stetler-Stevenson; G E Striker
Journal:  Am J Physiol       Date:  1993-06

Review 3.  The extracellular matrix in diabetic nephropathy.

Authors:  F N Ziyadeh
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

Review 4.  Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo.

Authors:  J Floege; E Eng; B A Young; R J Johnson
Journal:  Kidney Int Suppl       Date:  1993-01       Impact factor: 10.545

5.  Studies by competitive PCR of glomerulosclerosis in growth hormone transgenic mice.

Authors:  E P Peten; L J Striker; A Garcia-Perez; G E Striker
Journal:  Kidney Int Suppl       Date:  1993-01       Impact factor: 10.545

6.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.

Authors:  H Vlassara; H Fuh; Z Makita; S Krungkrai; A Cerami; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Mesangial deposition of type I collagen in human glomerulosclerosis.

Authors:  A D Glick; H R Jacobson; M A Haralson
Journal:  Hum Pathol       Date:  1992-12       Impact factor: 3.466

8.  Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus.

Authors:  P Bruneval; J M Foidart; D Nochy; J P Camilleri; J Bariety
Journal:  Hum Pathol       Date:  1985-05       Impact factor: 3.466

9.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Authors:  M Brownlee; H Vlassara; A Kooney; P Ulrich; A Cerami
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

10.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

Authors:  P Reichard; B Y Nilsson; U Rosenqvist
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

View more
  50 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 3.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

Review 4.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

5.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Authors:  Changyong Lu; John Cijiang He; Weijing Cai; Huixian Liu; Li Zhu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

6.  Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.

Authors:  Atsuhito Tone; Kenichi Shikata; Koichi Nakagawa; Masaaki Hashimoto; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2010-11-03       Impact factor: 2.801

7.  Epigenetic histone methylation modulates fibrotic gene expression.

Authors:  Guangdong Sun; Marpadga A Reddy; Hang Yuan; Linda Lanting; Mitsuo Kato; Rama Natarajan
Journal:  J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 10.121

Review 8.  Extracellular matrix and the kidney.

Authors:  P N Furness
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

9.  Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.

Authors:  Guihua Zhou; Cai Li; Lu Cai
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice.

Authors:  C W Yang; C C Yu; Y C Ko; C C Huang
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.